KaloBios Pharmaceuticals slips on a Q2 miss

KaloBios Pharmaceuticals (KBIO -2.3%) slips after its Q2 loss came in greater than Street expectations.

The company attributes the loss to increased spending for clinical trial programs and higher SG&A expenses associated with being a public company.

Contract revenues were $15K, down from the prior-year period's $2.99M.

From other sites
Comments (0)
Be the first to comment
DJIA (DIA) S&P 500 (SPY)
ETF Screener: Search and filter by asset class, strategy, theme, performance, yield, and much more
ETF Performance: View ETF performance across key asset classes and investing themes
ETF Investing Guide: Learn how to build and manage a well-diversified, low cost ETF portfolio
ETF Selector: An explanation of how to select and use ETFs